Patents by Inventor Gregory Henkel
Gregory Henkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230303569Abstract: The invention relates to compounds of structural formula 1 wherein A is independently N or C—R3, R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C6) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting ofType: ApplicationFiled: May 11, 2023Publication date: September 28, 2023Applicant: Arisan Therapeutics Inc.Inventors: Nadezda Sokolova, Kenneth McCormack, Gregory Henkel, Vidyasagar Reddy Gantla, Eric Brown
-
Patent number: 11548893Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.Type: GrantFiled: July 11, 2018Date of Patent: January 10, 2023Assignee: Arisan Therapeutics Inc.Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
-
Publication number: 20220281825Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting ofType: ApplicationFiled: April 21, 2022Publication date: September 8, 2022Applicant: Arisan Therapeutics Inc.Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
-
Publication number: 20220193038Abstract: Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.Type: ApplicationFiled: December 3, 2019Publication date: June 23, 2022Applicant: Arisan Therapeutics Inc.Inventors: Eric Brown, Vidyasagar Reddy Gantla, Nadezda Sokolova, Michael Bruno Plewe, Gregory Henkel, Kenneth McCormack
-
Patent number: 11352328Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting ofType: GrantFiled: July 7, 2017Date of Patent: June 7, 2022Assignee: Arisan Therapeutics Inc.Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadzeda V. Sokolova, Young-Jun Shin
-
Publication number: 20210171521Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.Type: ApplicationFiled: July 11, 2018Publication date: June 10, 2021Applicant: Arisan Therapeutics, Inc.Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
-
Publication number: 20200017514Abstract: Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.Type: ApplicationFiled: July 12, 2018Publication date: January 16, 2020Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadezda Sokolova
-
Publication number: 20190308938Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting ofType: ApplicationFiled: July 7, 2017Publication date: October 10, 2019Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
-
Publication number: 20140364450Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: April 15, 2014Publication date: December 11, 2014Inventors: Juan-Miguel Jimenez, Philip Collier, Gregory Henkel, Michael Liu, Timothy Neuberger, Jeremy Green
-
Publication number: 20140194444Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: January 15, 2014Publication date: July 10, 2014Inventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Patent number: 8735593Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: GrantFiled: March 5, 2013Date of Patent: May 27, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Patent number: 8664219Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: GrantFiled: June 2, 2010Date of Patent: March 4, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Publication number: 20130245273Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: March 5, 2013Publication date: September 19, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Patent number: 8518953Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: GrantFiled: June 2, 2010Date of Patent: August 27, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Albert Pierce, Jon Come, John Court, Gregory Henkel, Michael Liu, Timothy Neuberger, Huai Gao
-
Patent number: 8410133Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds, the methods of using the aforementioned compounds, and compounds in the treatment of various diseases, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: GrantFiled: June 2, 2010Date of Patent: April 2, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Publication number: 20110020377Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: June 2, 2010Publication date: January 27, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Albert Pierce, Jon Come, John Court, Gregory Henkel, Michael Liu, Timothy Neuberger, Huai Gao
-
Publication number: 20110020376Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: June 2, 2010Publication date: January 27, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
-
Publication number: 20110021559Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.Type: ApplicationFiled: June 2, 2010Publication date: January 27, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger